Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
22/05/2024 | 22:45 | GlobeNewswire Inc. | Adagene to Present at Investor Conferences in June | NASDAQ:ADAG | Adagene Inc |
29/03/2024 | 14:00 | GlobeNewswire Inc. | Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update | NASDAQ:ADAG | Adagene Inc |
07/03/2024 | 22:01 | GlobeNewswire Inc. | Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board | NASDAQ:ADAG | Adagene Inc |
01/03/2024 | 22:30 | Edgar (US Regulatory) | Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] | NASDAQ:ADAG | Adagene Inc |
27/02/2024 | 14:00 | GlobeNewswire Inc. | Adagene to Present at the Leerink Partners Global Biopharma Conference 2024 | NASDAQ:ADAG | Adagene Inc |
09/02/2024 | 12:08 | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:ADAG | Adagene Inc |
09/02/2024 | 12:00 | GlobeNewswire Inc. | Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stab | NASDAQ:ADAG | Adagene Inc |
16/01/2024 | 23:01 | GlobeNewswire Inc. | Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC) | NASDAQ:ADAG | Adagene Inc |
04/01/2024 | 11:00 | GlobeNewswire Inc. | Adagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI Symposium | NASDAQ:ADAG | Adagene Inc |
03/11/2023 | 17:00 | GlobeNewswire Inc. | Adagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 at SITC 2023 | NASDAQ:ADAG | Adagene Inc |
12/10/2023 | 14:00 | GlobeNewswire Inc. | Adagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody® ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting | NASDAQ:ADAG | Adagene Inc |
07/09/2023 | 12:00 | GlobeNewswire Inc. | Adagene to Present at Investor and Scientific Conferences in September | NASDAQ:ADAG | Adagene Inc |
31/08/2023 | 13:32 | GlobeNewswire Inc. | Adagene Reports Six Month Financial Results for 2023 and Provides Corporate Update | NASDAQ:ADAG | Adagene Inc |
04/05/2023 | 15:01 | Edgar (US Regulatory) | Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) | NASDAQ:ADAG | Adagene Inc |
04/05/2023 | 15:00 | GlobeNewswire Inc. | Adagene Achieves $3 Million Milestone in Collaboration with Exelixis for Successful Nomination of Second SAFEbody® Novel Masked Antibody-Drug Conjugate | NASDAQ:ADAG | Adagene Inc |
28/04/2023 | 13:03 | Edgar (US Regulatory) | Annual and Transition Report (foreign Private Issuer) (20-f) | NASDAQ:ADAG | Adagene Inc |
28/04/2023 | 13:00 | GlobeNewswire Inc. | Adagene Announces Updates to its Board of Directors | NASDAQ:ADAG | Adagene Inc |
18/04/2023 | 15:17 | GlobeNewswire Inc. | Adagene Presents Clinical Data for Anti-CTLA-4 SAFEbody® ADG126 Reinforcing Best-in-Class Safety Profile at Repeat Doses and Showing Early Efficacy Profile in Advanced/Metastatic Solid Tumors | NASDAQ:ADAG | Adagene Inc |
28/03/2023 | 22:30 | GlobeNewswire Inc. | Adagene Reports Full Year 2022 Financial Results and Provides Corporate Update | NASDAQ:ADAG | Adagene Inc |
14/03/2023 | 23:00 | GlobeNewswire Inc. | Adagene Announces Poster Presentations on Anti-CTLA-4 SAFEbody®, ADG126, at Upcoming American Association for Cancer Research (AACR) Annual Meeting in April | NASDAQ:ADAG | Adagene Inc |
06/03/2023 | 01:39 | GlobeNewswire Inc. | Adagene Appoints Professor Aurélien Marabelle to Scientific and Strategic Advisory Board | NASDAQ:ADAG | Adagene Inc |
09/02/2023 | 14:16 | Edgar (US Regulatory) | Amended Statement of Ownership (sc 13g/a) | NASDAQ:ADAG | Adagene Inc |
09/01/2023 | 13:00 | GlobeNewswire Inc. | Adagene Announces Interim Data Demonstrating Safety and Confirmed Clinical Responses of Anti-CTLA-4 SAFEbody® ADG126 up to 10 mg/kg with Repeat Cycles in Combination with Anti-PD-1 Therapy from Dose Escalation Portion of Phase 1b/2 Trial | NASDAQ:ADAG | Adagene Inc |
05/01/2023 | 22:01 | GlobeNewswire Inc. | Adagene to Present at the Biotech Showcase™ 2023 in San Francisco on January 9 | NASDAQ:ADAG | Adagene Inc |
16/12/2022 | 12:30 | GlobeNewswire Inc. | Adagene Announces Clinical Trial Collaboration to Evaluate Anti-CTLA-4 SAFEbody® ADG126 in Combination with Roche’s Standard-of-Care for First-Line Advanced Liver Cancer | NASDAQ:ADAG | Adagene Inc |
21/11/2022 | 22:05 | GlobeNewswire Inc. | Adagene Appoints Cuong Do to Board of Directors and Audit Committee | NASDAQ:ADAG | Adagene Inc |
10/11/2022 | 15:04 | GlobeNewswire Inc. | Adagene Announces Clinical Data at SITC 2022 on Anti-CTLA-4 NEObody™, ADG116, Showing Differentiated Safety and Anti-tumor Activity in Heavily Pre-treated Patients with Difficult-to-Treat Tumors | NASDAQ:ADAG | Adagene Inc |
11/10/2022 | 22:03 | GlobeNewswire Inc. | Adagene Announces Poster Presentations on Anti-CTLA-4 NEObody™, ADG116, at Upcoming Society for Immunotherapy of Cancer’s (SITC) Annual Meeting in November | NASDAQ:ADAG | Adagene Inc |
10/09/2022 | 10:13 | GlobeNewswire Inc. | Adagene Presents Interim Monotherapy Data at ESMO 2022 Showing Compelling Safety, Anti-Tumor Activity and Pharmacokinetics of Masked, Anti-CTLA-4 SAFEbody® ADG126 in Patients with Advanced Tumors | NASDAQ:ADAG | Adagene Inc |
30/08/2022 | 23:25 | GlobeNewswire Inc. | Adagene Reports Financial Results for the Six Months Ended June 30, 2022 and Provides Corporate Updates | NASDAQ:ADAG | Adagene Inc |